Ascletis Advances Novel Triple Agonist with Extended Half-Life
Event summary
- Ascletis Pharma selected ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development.
- NHP studies showed ASC37’s half-life was 7x longer than retatrutide’s, supporting once-monthly subcutaneous dosing.
- ASC37 demonstrates 5- to 4-fold greater in vitro potency compared to retatrutide across GLP-1R, GIPR, and GCGR.
- An IND submission to the FDA is anticipated in Q2 2026, with Phase I trials expected to begin in H2 2026.
The big picture
Ascletis is leveraging AI and proprietary technology to compete in the rapidly expanding obesity treatment market, currently dominated by Novo Nordisk and Eli Lilly. The extended half-life and enhanced potency of ASC37, if validated in clinical trials, could offer a differentiated profile and potentially capture significant market share. The company’s strategy of combining ASC37 with ASC36 highlights a broader approach to metabolic disease management.
What we're watching
- Clinical Efficacy
- The success of ASC37 will hinge on demonstrating comparable or superior clinical efficacy to existing GLP-1R agonists and dual agonists in Phase I and subsequent trials, particularly given the crowded market.
- Regulatory Pathway
- The FDA’s review of the IND submission and subsequent clinical trial data will be critical, as the novel triple agonist mechanism may require additional scrutiny and data to support approval.
- Manufacturing Scale
- Ascletis’ ability to scale up production of ASC37’s SQ depot formulations to meet potential demand will be a key factor in its commercial success, given the complexity of peptide manufacturing.
Related topics